Mount Sinai Tisch Cancer Institute (TCI), in collaboration with the Valley Health System, seeks an experienced Hematologic Oncologist to develop and direct a new Stem Cell Transplantation and Cellular Therapy Service at the Valley Health System.
The Medical Director will be based initially at Mount Sinai as a member of the Multiple Myeloma and the Bone Marrow and Stem Cell Transplant Programs. Protected time will be provided for planning the Stem Cell Transplantation and Cellular Therapy Service at Valley-Mount Sinai Comprehensive Cancer Care. It is anticipated that over the course of 3 years the Medical Director will progressively spend more clinical, research, and administrative time at The Valley Health System for on-site development and implementation of the Service while maintaining a presence at the MSHS. In collaboration with clinical and administrative leaders from both organizations, the Medical Director will be responsible for preparing the regulatory documents, including policies and procedures, and other materials required for activating and accrediting the Stem Cell Transplantation and Cellular Therapy Service at Valley. It is anticipated that over a period of 1 to 2 years, the Medical Director will progressively spend more clinical, research, and administrative time at The Valley Health System for on-site development and implementation of the Service. The Medical Director will be responsible for the overall quality of the Service, overseeing patient care, research, and education.
The Tisch Cancer Center
The Tisch Cancer Institute (TCI), a National Cancer Institute-designated cancer center, employs a multidisciplinary approach to cancer research and treatment, with the goal of advancing clinical breakthroughs that help prevent and eradicate cancer. The mission of The Tisch Cancer Institute is to advance basic, clinical and population health cancer research, in order to prevent cancer in healthy individuals and improve the lives of cancer patients and their families in our diverse communities. Established in 2008 through the generosity of James and Merryl Tisch, The TCI has recruited more than 80 prominent scientists and physicians whose expertise spans basic, clinical, and population science research. Together they have developed innovative and translational research programs that build upon Mount Sinai’s history of medical discovery and outstanding patient care. They continually collaborate and work in partnership with multiple disciplines across the Mount Sinai Health System to advance novel treatments, such as immunotherapy, that offer hope for those at risk for or living with cancer. The TCI is an integral part of the Mount Sinai Health System and is continually on the forefront of medical and scientific training, biomedical research, and patient care. The Tisch Cancer Hospital will open by 2027, will open with new "patient-centric" treatment initiatives, inspired by the promise of the state-of-the-art facility.
Multiple Myeloma Center of Excellence
Mount Sinai’s Center of Excellence for Multiple Myeloma is known throughout the world as a leader in integrating patient care and translational research. With four locations, 55 clinicians and staff, 36 scientists and research personnel, and a high patient volume, that continues to grow. Our patient base is notably diverse, offering physicians significant opportunities to make an impact on advancing treatment and supporting health equity through research and clinical initiatives.
Multiple myeloma program has a diverse clinical trials portfolio, including first-in-human and phase 1 and 2 clinical trials, CAR-T and Bi-specific antibody trials. Our program has contributed to every new multiple myeloma drug that has been introduced over the past 10+ years, and we continue to play a significant role in drug development.
The Bone Marrow & Stem Cell Transplantation Program at Mount Sinai is a Foundation for the Accreditation of Cellular Therapy (FACT)-accredited Bone Marrow/Stem Cell Collection, Processing, and Transplant Site. Our program performs 300 cell therapy procedures annually. These include all modalities of immune effector cells, autologous and allogeneic stem cell transplants. We have a very active research portfolio including protocols from cooperative groups, investigator-initiated trials, and industry-sponsored studies. Our program has a cellular therapy service to oversee CARTs and other immune effector cell treatments. We offer both commercial and investigational CAR T-cell products to patients and continue to onboard additional commercial products as they become FDA-approved. CAR T-cell therapy is FACT accredited at Mount Sinai under the Bone Marrow & Stem Cell Transplantation Program’s Immune Effector Cell accreditation.
The Bone Marrow & Stem Cell Transplantation Program at Mount Sinai is a Foundation for the Accreditation of Cellular Therapy (FACT)-accredited Bone Marrow/Stem Cell Collection, Processing, and Transplant Site. Our program performs 300 cell therapy procedures annually. These include all modalities of immune effector cells, autologous and allogeneic stem cell transplants. We have a very active research portfolio including protocols from cooperative groups, investigator initiated trials, and industry-sponsored studies. Our program has a cellular therapy service to oversee CARTs and other immune effector cell treatments. We offer both commercial and investigational CAR T-cell products to patients, and continue to onboard additional commercial products as they become FDA-approved. CAR T-cell therapy is FACT accredited at Mount Sinai under the Bone Marrow & Stem Cell Transplantation Program’s Immune Effector Cell accreditation.
Valley Health System
Distinguished by its culture of excellence and by its talented medical staff, the Valley Health System has a long tradition of outstanding patient-centered care. Valley has joined forces with New York's Mount Sinai Health System to bring exceptional and distinctive care to patients in northern New Jersey. Valley-Mount Sinai Comprehensive Cancer Care provides unique clinical programs for our patients, as well as educational and research opportunities for our staff. We have QOPI certification and accreditation from the Commission on Cancer of the American College of Surgeons. Valley’s new state-of-the-art hospital, directly across from our cancer center, is scheduled to open in April 2024, and will anchor a 40-acre healthcare campus.
Valley-Mount Sinai Comprehensive Cancer offer a supportive and collegial environment, and the potential for professional growth. An on-site team at Valley provides support for our active research program, which includes investigator-initiated trials in addition to NCTN and industry-sponsored research. Teaching oportunities will be available in 2024 when Valley opens its Internal Medicine Residency. A Hematology/Oncology fellowship is planned for 2026.
Qualifications:
Primary Duties and Responsibilities:
Program Director, Stem Cell Transplantation and Cellular Therapy Program, Valley-Mount Sinai Comprehensive Cancer Care
Hematology/Oncology Physician, Oncology Services
Please specify Job Title of interest and send CV with Cover Letter to:
Alex Cano
Executive Director Physician Recruitment
Mount Sinai Health System
Alex.cano@mountsinai.org
Strength Through Diversity
The Mount Sinai Health System believes that diversity, equity, and inclusion are key drivers for excellence. We share a common devotion to delivering exceptional patient care. When you join us, you become a part of Mount Sinai’s unrivaled record of achievement, education, and advancement as we revolutionize medicine together. We invite you to participate actively as a part of the Mount Sinai Health System team by:
We work hard to acquire and retain the best people and to create an inclusive, welcoming and nurturing work environment where all feel they are valued, belong and are able to professional advance. We share the belief that all employees, regardless of job title or expertise contribute to the patient experience and quality of patient care.
Explore more about this opportunity and how you can help us write a new chapter in our history!
“About the Mount Sinai Health System:
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with more than 43,000 employees working across eight hospitals, more than 400 outpatient practices, more than 300 labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time — discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it. Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 7,400 primary and specialty care physicians; 13 joint-venture outpatient surgery centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and more than 30 affiliated community health centers. We are consistently ranked by U.S. News & World Report's Best Hospitals, receiving high "Honor Roll" status, and are highly ranked: No. 1 in Geriatrics and top 20 in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Neurology/Neurosurgery, Orthopedics, Pulmonology/Lung Surgery, Rehabilitation, and Urology. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 12 in Ophthalmology. U.S. News & World Report’s “Best Children’s Hospitals” ranks Mount Sinai Kravis Children's Hospital among the country’s best in several pediatric specialties. The Icahn School of Medicine at Mount Sinai is ranked No. 14 nationwide in National Institutes of Health funding and in the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges. Newsweek’s “The World’s Best Smart Hospitals” ranks The Mount Sinai Hospital as No. 1 in New York and in the top five globally, and Mount Sinai Morningside in the top 20 globally.
The Mount Sinai Health System is an equal opportunity employer. We comply with applicable Federal civil rights laws and does not discriminate, exclude, or treat people differently on the basis of race, color, national origin, age, religion, disability, sex, sexual orientation, gender identity, or gender expression. We are passionately committed to addressing racism and its effects on our faculty, staff, students, trainees, patients, visitors, and the communities we serve. Our goal is for Mount Sinai to become an anti-racist health care and learning institution that intentionally addresses structural racism.”
EOE Minorities/Women/Disabled/Veterans
Read Full Description